In drug-sensitive and resistant tumor cell lines that primarily express PKM2, it is manifested by the determination of cellular lactate production and glucose consumption that Shikonin (alkannin) significantly suppresses the glycolytic rate [80]. This evidence concerns the gene PKM and neoplasm.